MRI Signal Intensity and Electron Ultrastructure Classification Predict the Long-Term Outcome of Skull Base Chordomas

REFERENCES

1. 1.↵
   1. McMaster ML,
   2. Goldstein AM,
   3. Bromley CM, et al

   . Chordoma: incidence and survival patterns in the United States, 1973. Cancer Causes Control 2001;12:1–11 doi:10.1023/A:1008947301735 pmid:11227920

   CrossRefPubMedWeb of Science
2. 2.↵
   1. Stacchiotti S,
   2. Sommer J

   ; Chordoma Global Consensus Group. Building a global consensus approach to chordoma: a position paper from the medical and patient community. Lancet Oncol 2015;16:e71–83 doi:10.1016/S1470-2045(14)71190-8 pmid:25638683

   CrossRefPubMed
3. 3.↵
   1. Erdem E,
   2. Angtuaco EC,
   3. Van Hemert R, et al

   . Comprehensive review of intracranial chordoma. Radiographics 2003;23:995–1009 doi:10.1148/rg.234025176 pmid:12853676

   CrossRefPubMed
4. 4.↵
   1. Walcott BP,
   2. Nahed BV,
   3. Mohyeldin A, et al

   . Chordoma: current concepts, management, and future directions. Lancet Oncol 2012;13:e69–76 doi:10.1016/S1470-2045(11)70337-0 pmid:22300861

   CrossRefPubMedWeb of Science
5. 5.↵
   1. Tauziede-Espariat A,
   2. Bresson D,
   3. Polivka M, et al

   . Prognostic and therapeutic markers in chordomas: a study of 287 tumors. J Neuropathol Exp Neurol 2016;75:111–20 doi:10.1093/jnen/nlv010 pmid:26733585

   CrossRefPubMed
6. 6.↵
   1. Beccaria K,
   2. Tauziede-Espariat A,
   3. Monnien F, et al

   . Pediatric chordomas: results of a multicentric study of 40 children and proposal for a histopathological prognostic grading system and new therapeutic strategies. J Neuropathol Exp Neurol 2018;77:207–15 doi:10.1093/jnen/nlx118 pmid:29361006

   CrossRefPubMed
7. 7.↵
   1. Zhang S,
   2. Bai J,
   3. Li M, et al

   . Predictive value of transforming growth factor-alpha and Ki-67 for the prognosis of skull base chordoma. World Neurosurg 2019;129:e199–206 doi:10.1016/j.wneu.2019.05.110 pmid:31125781

   CrossRefPubMed
8. 8.↵
   1. Zhai Y,
   2. Bai J,
   3. Wang S, et al

   . Analysis of clinical factors and PDGFR-beta in predicting prognosis of patients with clival chordoma. J Neurosurg 2018;129:1429–37 doi:10.3171/2017.6.JNS17562 pmid:29303447

   CrossRefPubMed
9. 9.↵
   1. Li M,
   2. Zhai Y,
   3. Bai J, et al

   . SNF5 as a prognostic factor in skull base chordoma. J Neurooncol 2018;137:139–46 doi:10.1007/s11060-017-2706-3 pmid:29222701

   CrossRefPubMed
10. 10.↵
    1. Zhai Y,
    2. Bai J,
    3. Wang S, et al

    . Differences in dural penetration of clival chordomas are associated with different prognosis and expression of platelet-derived growth factor receptor-beta. World Neurosurg 2017;98:288–95 doi:10.1016/j.wneu.2016.07.096 pmid:27506406

    CrossRefPubMed
11. 11.↵
    1. Tian K,
    2. Wang L,
    3. Wang K, et al

    . Analysis of clinical features and outcomes of skull base chordoma in different age-groups. World Neurosurg 2016;92:407–17 doi:10.1016/j.wneu.2016.05.035 pmid:27237421

    CrossRefPubMed
12. 12.↵
    1. Wang L,
    2. Wu Z,
    3. Tian K, et al

    . Clinical features and surgical outcomes of patients with skull base chordoma: a retrospective analysis of 238 patients. J Neurosurg 2017;127:1257–67 doi:10.3171/2016.9.JNS16559 pmid:28059654

    CrossRefPubMed
13. 13.↵
    1. Bai J,
    2. Zhai Y,
    3. Wang S, et al

    . Prognostic value of a category based on electron microscopic features of clival chordomas. World Neurosurg 2017;99:282–87 doi:10.1016/j.wneu.2016.11.117 pmid:27916725

    CrossRefPubMed
14. 14.↵
    1. Sung MS,
    2. Lee GK,
    3. Kang HS, et al

    . Sacrococcygeal chordoma: MR imaging in 30 patients. Skeletal Radiol 2005;34:87–94 doi:10.1007/s00256-004-0840-4 pmid:15480648

    CrossRefPubMedWeb of Science
15. 15.↵
    1. Yeom KW,
    2. Lober RM,
    3. Mobley BC, et al

    . Diffusion-weighted MRI: distinction of skull base chordoma from chondrosarcoma. AJNR Am J Neuroradiol 2013;34:1056–61 doi:10.3174/ajnr.A3333 pmid:23124635

    Abstract/FREE Full Text
16. 16.↵
    1. Tian K,
    2. Wang L,
    3. Ma J, et al

    . MR imaging grading system for skull base chordoma. AJNR Am J Neuroradiol 2017;38:1206–11 doi:10.3174/ajnr.A5152 pmid:28428207

    Abstract/FREE Full Text
17. 17.↵
    1. Lin E,
    2. Scognamiglio T,
    3. Zhao Y, et al

    . Prognostic implications of gadolinium enhancement of skull base chordomas. AJNR Am Neuroradiol 2018;39:1509–15 doi:10.3174/ajnr.A5714 pmid:29903925

    Abstract/FREE Full Text
18. 18.↵
    1. Yin P,
    2. Mao N,
    3. Zhao C, et al

    . A triple-classification radiomics model for the differentiation of primary chordoma, giant cell tumor, and metastatic tumor of sacrum based on T2-weighted and contrast-enhanced T1-weighted MRI. J Magn Reson Imaging 2019;49:752–59 doi:10.1002/jmri.26238 pmid:30430686

    CrossRefPubMed
19. 19.↵
    1. Li L,
    2. Wang K,
    3. Ma X, et al

    . Radiomic analysis of multiparametric magnetic resonance imaging for differentiating skull base chordoma and chondrosarcoma. Eur J Radiol 2019;118:81–87 doi:10.1016/j.ejrad.2019.07.006 pmid:31439263

    CrossRefPubMed
20. 20.↵
    1. von Witzleben A,
    2. Goerttler LT,
    3. Lennerz J, et al

    . In chordoma, metastasis, recurrences, Ki-67 index, and a matrix-poor phenotype are associated with patients’ shorter overall survival. Eur Spine J 2016;25:4016–24 doi:10.1007/s00586-015-4242-1 pmid:26399506

    CrossRefPubMed
21. 21.↵
    1. Tateishi U,
    2. Hasegawa T,
    3. Beppu Y, et al

    . Prognostic significance of MRI findings in patients with myxoid-round cell liposarcoma. AJR Am J Roentgenol 2004;182:725–31 doi:10.2214/ajr.182.3.1820725 pmid:14975976

    CrossRefPubMed
22. 22.↵
    1. Santamaria G,
    2. Velasco M,
    3. Bargallo X, et al

    . Radiologic and pathologic findings in breast tumors with high signal intensity on T2-weighted MR images. Radiographics 2010;30:533–48 doi:10.1148/rg.302095044 pmid:20228333

    CrossRefPubMed
23. 23.↵
    1. Shih AR,
    2. Cote GM,
    3. Chebib I, et al

    . Clinicopathologic characteristics of poorly differentiated chordoma. Mod Pathol 2018;31:1237–45 doi:10.1038/s41379-018-0002-1 pmid:29483606

    CrossRefPubMed
24. 24.↵
    1. Santos P,
    2. Peck KK,
    3. Arevalo-Perez J, et al

    . T1-weighted dynamic contrast-enhanced MR perfusion imaging characterizes tumor response to radiation therapy in chordoma. AJNR Am J Neuroradiol 2017;38:2210–16 doi:10.3174/ajnr.A5383 pmid:28912284

    Abstract/FREE Full Text
25. 25.↵
    1. Wei W,
    2. Wang K,
    3. Liu Z, et al

    . Radiomic signature: a novel magnetic resonance imaging-based prognostic biomarker in patients with skull base chordoma. Radiother Oncol 2019;141:239–46 doi:10.1016/j.radonc.2019.10.002 pmid:31668985

    CrossRefPubMed
26. 26.↵
    1. Zhai Y,
    2. Bai J,
    3. Wang S, et al

    . Aberrant expression of extracellular signal-regulated kinase and 15-hydroxyprostaglandin dehydrogenase indicates radiation resistance and poor prognosis for patients with clival chordomas. World Neurosurg 2018;115:e146–51 doi:10.1016/j.wneu.2018.03.216 pmid:29649649

    CrossRefPubMed
27. 27.↵
    1. Sasaki T,
    2. Moritani T,
    3. Belay A, et al

    . Role of the apparent diffusion coefficient as a predictor of tumor progression in patients with chordoma. AJNR Am J Neuroradiol 2018;39:1316–21 doi:10.3174/ajnr.A5664 pmid:29724767

    Abstract/FREE Full Text
28. 28.↵
    1. Buizza G,
    2. Molinelli S,
    3. D’Ippolito E, et al

    . MRI-based tumour control probability in skull-base chordomas treated with carbon-ion therapy. Radiother Oncol 2019;137:32–37 doi:10.1016/j.radonc.2019.04.018 pmid:31051372

    CrossRefPubMed